These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8346713)

  • 1. Cytokine regulation of iron metabolism: effect of low-dose interleukin-2 subcutaneous therapy on ferritin, transferrin and iron blood concentrations in cancer patients.
    Lissoni P; Cazzaniga M; Ardizzoia A; Rossini F; Fiorelli G; Tancini G; Pittalis S; Barni S
    J Biol Regul Homeost Agents; 1993; 7(1):31-3. PubMed ID: 8346713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactivation of a normal endogenous secretion of interleukin-2 in metastatic cancer patients by a chronic subcutaneous injection of interleukin-2.
    Di Felice G; Fumagalli L; Majorca F; Barni S; Ardizzoia A; Tancini G; Lissoni P
    J Biol Regul Homeost Agents; 1996; 10(4):98-9. PubMed ID: 9604779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cortisol response to an acute injection of IL-2 in healthy subjects and cancer patients: a first immunoneuroendocrine standardized clinical test to explore the interactions between immune and neuroendocrine systems.
    Lissoni P; Messina G; Brivio F; Rovelli F; Di Fede G; Mainini E; Veronese E
    J Biol Regul Homeost Agents; 2005; 19(3-4):141-4. PubMed ID: 16602629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiopathology of IL-12 in human solid neoplasms: blood levels of IL-12 in early or advanced cancer patients, and their variations with surgery and immunotherapy.
    Lissoni P; Mengo S; Mandalà M; Mauri E; Brivio F; Rovelli F; Confalonieri G; Longarini R; Bonfante A; Folli D; Meregalli S; Barni S; Tancini G; Giani L
    J Biol Regul Homeost Agents; 1998; 12(1-2):38-41. PubMed ID: 9677534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II study of subcutaneous low-dose interleukin-2 plus erythropoietin in metastatic renal cell carcinoma progressing on interleukin-2 alone.
    Lissoni P; Rovelli F; Baiocco N; Tangini G; Fumagalli L
    Anticancer Res; 2001; 21(1B):777-9. PubMed ID: 11299843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transferrin and ferritin as laboratory indices of body iron deposits].
    Bobilewicz D; Jabłońska E; Iwanowska M; Zborowska H; Jasińska A
    Pol Tyg Lek; 1995 Oct; 50(40-44):42-4. PubMed ID: 8650058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of transferrin receptor and ferritin H-chain mRNA are associated with clinical and histopathological prognostic indicators in breast cancer.
    Yang DC; Wang F; Elliott RL; Head JF
    Anticancer Res; 2001; 21(1B):541-9. PubMed ID: 11299801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Serum iron parameters in chronic hepatitis C patients and comparison of the results before and during antiviral treatment].
    Bolewska B; Wojtacha A; Juszczyk J; Przedwojewski M
    Pol Merkur Lekarski; 2005 May; 18(107):552-5. PubMed ID: 16161954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Normalization of idiopathic arterial hypertension following cancer immunotherapy with interleukin-2.
    Lissoni P; Bastone A; Barni S; Tancini G; Galli MA
    J Biol Regul Homeost Agents; 1994; 8(2):65-6. PubMed ID: 7863816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Changes in iron metabolism in Osler-Rendu disease].
    Livandovskiĭ IuA
    Ter Arkh; 1989; 61(2):109-10. PubMed ID: 2727910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of cancer-related thrombocytopenia by low-dose subcutaneous interleukin-2 plus the pineal hormone melatonin: a biological phase II study.
    Lissoni P; Barni S; Brivio F; Rossini F; Fumagalli L; Tancini G
    J Biol Regul Homeost Agents; 1995; 9(2):52-4. PubMed ID: 9127633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between pretreatment serum levels of neopterin and response to interleukin-2 immunotherapy in cancer patients.
    Lissoni P; Barni S; Ardizzoia A; Scardino E; Tancini G; Viganò MG
    J Biol Regul Homeost Agents; 1995; 9(1):21-3. PubMed ID: 8553904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Melatonin corrects reticuloendothelial blockade and iron status in haemodialysed patients.
    Labonia W; Rubio D; Arias C
    Nephrology (Carlton); 2005 Dec; 10(6):583-7. PubMed ID: 16354241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels.
    Dale JC; Burritt MF; Zinsmeister AR
    Am J Clin Pathol; 2002 May; 117(5):802-8. PubMed ID: 12090432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Postoperative changes in serum levels of iron, transferrin and ferritin in surgical patients].
    Hirota M; Sakamoto K; Yamaguchi Y; Katafuchi S; Ikei S; Mori K; Akagi M
    Nihon Geka Gakkai Zasshi; 1987 Nov; 88(11):1536-41. PubMed ID: 3431535
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of prohepcidin, inflammatory markers and iron status in resistance to rhEPO therapy in hemodialysis patients.
    Costa E; Pereira BJ; Rocha-Pereira P; Rocha S; Reis F; Castro E; Teixeira F; Miranda V; do Sameiro Faria M; Loureiro A; Quintanilha A; Belo L; Santos-Silva A
    Am J Nephrol; 2008; 28(4):677-83. PubMed ID: 18354252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum parameters of iron metabolism in patients with breast cancer.
    Ulbrich EJ; Lebrecht A; Schneider I; Ludwig E; Koelbl H; Hefler LA
    Anticancer Res; 2003; 23(6D):5107-9. PubMed ID: 14981974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.